Thyroid Eye Disease: Clinical Trials

2 trials for Thyroid Eye Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 42Completed 2

Follow Thyroid Eye Disease: new trials by email Literature Review of Thyroid Eye Disease trials Research Report on Thyroid Eye Disease

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
Teprotumumab, Placebo - Thyroid Eye Disease
Phase 4CompletedAmgen3132021-09-162026-08-21
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
TEPEZZA, Placebo - Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Phase 4CompletedAmgen622021-09-022024-07-01

Narrower conditions

Graves Ophthalmopathy (2)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Exophthalmos (1)  ·  Sedentary Behavior (1)

Broader conditions

Autoimmune Diseases (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Endocrine System Diseases (2)  ·  Eye Diseases (2)  ·  Eye Diseases, Hereditary (2)  ·  Genetic Diseases, Inborn (2)  ·  Goiter (2)  ·  Graves Disease (2)  ·  Hyperthyroidism (2)  ·  Immune System Diseases (2)  ·  Orbital Diseases (2)  ·  Thyroid Diseases (2)  ·  Behavior (1)  ·  Bronchial Diseases (1)  ·  Bronchiolitis (1)

Interventions

teprotumumab (2)  ·  Saline Solution (1)  ·  Sodium Chloride (1)

Sponsors

Amgen (2)

Countries

United States (2)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Spain (1)  ·  United Kingdom (1)

Results publications

PMID 42837042